<DOC>
	<DOC>NCT00100477</DOC>
	<brief_summary>The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).</brief_summary>
	<brief_title>Use of Topotecan in Patients With Refractory Acute Leukemia</brief_title>
	<detailed_description>The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients in the following disease categories will be considered eligible for this study: Any acute leukemia beyond an initial attempt to induce a remission or after relapse Chronic Myelogenous Leukemia in Blast Phase Refractory Multiple Myeloma Refractory nonHodgkin's and Hodgkin's Lymphoma Patients must be more than 14 days beyond prior myelotoxic chemotherapy Several other eligibility criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Clinical Trials</keyword>
</DOC>